Hiwatashi N, Morimoto T, Fukao A, Sato H, Sugahara N, Hisamichi S, Toyota T
Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai.
Jpn J Cancer Res. 1993 Nov;84(11):1110-2. doi: 10.1111/j.1349-7006.1993.tb02809.x.
There is as yet no firm evidence showing that mass screening for colorectal cancer using fecal occult blood tests (FOBTs) reduces the mortality from this cancer. Therefore we evaluated the effectiveness of the screening by a case-control study in Miyagi Prefecture, Japan. The study included as case subjects 28 individuals who had died from colorectal cancer and had had an opportunity to participate in the mass screening before the date of diagnosis as colorectal cancer, and 3 controls for each case subject randomly selected from residents who were alive on the date of death of case subjects and matched by sex, age (within 3 years) and living area using residential files. For each set, i.e., a case subject and 3 controls, screening histories before the date of the diagnosis of the case as colorectal cancer were examined. Both the case subjects and the controls who had participated in the screening at least once within 3 years before the date of diagnosis of the case were classified as "screened." The 28 case subjects consisted of 12 males and 16 females (average age: 60.8 years). The odds ratio of death from colorectal cancer for the screened versus the non-screened persons was 0.24 (95% confidence interval = 0.08-0.76) by the Mantel-Haenszel method. The present study suggests that mass screening using FOBTs for colorectal cancer significantly reduces the mortality from this cancer epidemiologically.
目前尚无确凿证据表明使用粪便潜血试验(FOBTs)进行结直肠癌大规模筛查能降低该癌症的死亡率。因此,我们通过一项病例对照研究对日本宫城县的筛查效果进行了评估。该研究纳入了28名因结直肠癌死亡且在被诊断为结直肠癌之前有机会参与大规模筛查的个体作为病例组,以及从病例组个体死亡日期时仍在世的居民中随机选取的、按性别、年龄(相差3岁以内)和居住地区使用居民档案进行匹配的、每名病例组个体对应3名对照组成的对照组。对于每一组,即一名病例组个体和3名对照组个体,调查在病例组个体被诊断为结直肠癌之前的筛查历史。在病例组个体被诊断为结直肠癌之前3年内至少参与过一次筛查的病例组个体和对照组个体均被归类为“接受过筛查”。28名病例组个体包括12名男性和16名女性(平均年龄:60.8岁)。采用Mantel-Haenszel法计算,接受过筛查的人与未接受过筛查的人相比,死于结直肠癌的优势比为0.24(95%置信区间 = 0.08 - 0.76)。本研究表明,从流行病学角度来看,使用FOBTs进行结直肠癌大规模筛查可显著降低该癌症的死亡率。